Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:10425382rdf:typepubmed:Citationlld:pubmed
pubmed-article:10425382lifeskim:mentionsumls-concept:C0031330lld:lifeskim
pubmed-article:10425382lifeskim:mentionsumls-concept:C2003888lld:lifeskim
pubmed-article:10425382lifeskim:mentionsumls-concept:C0021888lld:lifeskim
pubmed-article:10425382lifeskim:mentionsumls-concept:C1299003lld:lifeskim
pubmed-article:10425382lifeskim:mentionsumls-concept:C0007036lld:lifeskim
pubmed-article:10425382lifeskim:mentionsumls-concept:C0038760lld:lifeskim
pubmed-article:10425382lifeskim:mentionsumls-concept:C0220781lld:lifeskim
pubmed-article:10425382lifeskim:mentionsumls-concept:C1883254lld:lifeskim
pubmed-article:10425382lifeskim:mentionsumls-concept:C0456387lld:lifeskim
pubmed-article:10425382lifeskim:mentionsumls-concept:C1704419lld:lifeskim
pubmed-article:10425382pubmed:issue4lld:pubmed
pubmed-article:10425382pubmed:dateCreated1999-9-28lld:pubmed
pubmed-article:10425382pubmed:abstractTextReaction of 20 aromatic/heterocyclic sulfonamides containing a free amino, imino, hydrazino or hydroxyl group, with picolinic acid in the presence of carbodiimide derivatives afforded a series of water-soluble (as hydrochloride or triflate salts) compounds. The new derivatives were assayed as inhibitors of three carbonic anhydrase (CA) isozymes, CA I, II (cytosolic forms) and IV (membrane-bound form). Efficient inhibition was observed against all three isozymes, but especially against CA II and CA IV (in nanomolar range), the two isozymes known to play a critical role in aqueous humor secretion within the ciliary processes of the eye. Some of the best inhibitors synthesized were applied as 2% water solutions directly into the eye of normotensive or glaucomatous albino rabbits. Very strong intraocular pressure (IOP) lowering was observed for many of them, and the active drug was detected in eye tissues and fluids. This result prompted us to reanalyze the synthetic work done by other groups for the design of water soluble, topically effective antiglaucoma sulfonamides. According to these researchers, the IOP lowering effect is due to the intrinsic nature of the specific heterocyclic sulfonamide considered, among which the thienothiopyran-2-sulfonamide derivatives represent the best studied case. Indeed, the first agents developed for such applications, such as dorzolamide, are derivatives of this ring system. In order to prove that the tail (in this case the picolinoyl moiety) conferring water solubility to a sulfonamide CA inhibitor is critically important for its topical effectiveness, similarly to the ring to which the sulfonamido group is grafted, we also prepared a dorzolamide derivative to which the picolinoyl moiety was attached. This new compound is more water soluble than dorzolamide (as hydrochloride salt), behaves as a strong CA II inhibitor, and acts similarly to the parent derivative in lowering IOP in experimental animals. Thus, it seems that the tail conferring water solubility is more important for topical activity as antiglaucoma drug, than the heterocyclic/aromatic ring to which the sulfonamido moiety is grafted.lld:pubmed
pubmed-article:10425382pubmed:languageenglld:pubmed
pubmed-article:10425382pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10425382pubmed:citationSubsetIMlld:pubmed
pubmed-article:10425382pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10425382pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10425382pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10425382pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10425382pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10425382pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10425382pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10425382pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10425382pubmed:statusMEDLINElld:pubmed
pubmed-article:10425382pubmed:monthAuglld:pubmed
pubmed-article:10425382pubmed:issn0928-0987lld:pubmed
pubmed-article:10425382pubmed:authorpubmed-author:ScozzafavaAAlld:pubmed
pubmed-article:10425382pubmed:authorpubmed-author:MincioneGGlld:pubmed
pubmed-article:10425382pubmed:authorpubmed-author:MincioneFFlld:pubmed
pubmed-article:10425382pubmed:authorpubmed-author:BrigantiFFlld:pubmed
pubmed-article:10425382pubmed:authorpubmed-author:SupuranC TCTlld:pubmed
pubmed-article:10425382pubmed:authorpubmed-author:MenabuoniLLlld:pubmed
pubmed-article:10425382pubmed:issnTypePrintlld:pubmed
pubmed-article:10425382pubmed:volume8lld:pubmed
pubmed-article:10425382pubmed:ownerNLMlld:pubmed
pubmed-article:10425382pubmed:authorsCompleteYlld:pubmed
pubmed-article:10425382pubmed:pagination317-28lld:pubmed
pubmed-article:10425382pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:10425382pubmed:meshHeadingpubmed-meshheading:10425382...lld:pubmed
pubmed-article:10425382pubmed:meshHeadingpubmed-meshheading:10425382...lld:pubmed
pubmed-article:10425382pubmed:meshHeadingpubmed-meshheading:10425382...lld:pubmed
pubmed-article:10425382pubmed:meshHeadingpubmed-meshheading:10425382...lld:pubmed
pubmed-article:10425382pubmed:meshHeadingpubmed-meshheading:10425382...lld:pubmed
pubmed-article:10425382pubmed:meshHeadingpubmed-meshheading:10425382...lld:pubmed
pubmed-article:10425382pubmed:meshHeadingpubmed-meshheading:10425382...lld:pubmed
pubmed-article:10425382pubmed:meshHeadingpubmed-meshheading:10425382...lld:pubmed
pubmed-article:10425382pubmed:meshHeadingpubmed-meshheading:10425382...lld:pubmed
pubmed-article:10425382pubmed:meshHeadingpubmed-meshheading:10425382...lld:pubmed
pubmed-article:10425382pubmed:meshHeadingpubmed-meshheading:10425382...lld:pubmed
pubmed-article:10425382pubmed:meshHeadingpubmed-meshheading:10425382...lld:pubmed
pubmed-article:10425382pubmed:meshHeadingpubmed-meshheading:10425382...lld:pubmed
pubmed-article:10425382pubmed:meshHeadingpubmed-meshheading:10425382...lld:pubmed
pubmed-article:10425382pubmed:meshHeadingpubmed-meshheading:10425382...lld:pubmed
pubmed-article:10425382pubmed:year1999lld:pubmed
pubmed-article:10425382pubmed:articleTitleCarbonic anhydrase inhibitors. Part 71. Synthesis and ocular pharmacology of a new class of water-soluble, topically effective intraocular pressure lowering sulfonamides incorporating picolinoyl moieties.lld:pubmed
pubmed-article:10425382pubmed:affiliationUniversità degli Studi, Laboratorio di Chimica Inorganica e Bioinorganica, Via Gino Capponi 7, I-50121, Firenze, Italy. cts@asl.cerm.unifi.itlld:pubmed
pubmed-article:10425382pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:10425382pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed